

Subgroup	No. of patients	IMNI	no IMNI		HR(95%CI)	p value
<b>Chemotherapy</b>						
NAC	217	103(47.5%)	114(52.5%)		0.451(0.259–0.785)	<0.001
Adjuvant	630	287(45.6%)	343(54.4%)		0.539(0.389–0.747)	<0.001
<b>Molecular subtype</b>						
TNBC	142	68(47.9%)	74(52.1%)		(0.306–1.254)	0.184
other	705	380(54.0%)	324(46.0%)		0.511(0.377–0.693)	<0.001
<b>N stage</b>						
N0	106	52(49.0%)	54(51.0%)		0.257(0.052–1.268)	0.095
N1	317	151(47.6%)	166(52.4%)		0.543(0.316–0.934)	0.027
N2	255	108(42.4%)	147(57.6%)		0.741(0.462–1.189)	0.214
N3	169	104(61.5%)	65(38.5%)		0.460(0.291–0.727)	0.001
<b>T stage</b>						
T1	358	150(41.9%)	208(58.1%)		0.471(0.296–0.747)	0.001
T2	374	182(48.7%)	192(51.3%)		0.568(0.380–0.848)	0.006
T3–4	61	34(55.7%)	27(44.3%)		0.909(0.402–2.053)	0.818
<b>pCR</b>						
pCR	41	20(48.8%)	21(51.2%)		0.311(0.032–2.974)	0.31
<b>Tumor location</b>						
Latera	466	201(43.1%)	264(56.9%)		0.584(0.401–0.850)	0.005
Central/media	381	191(50.1%)	190(49.9%)		0.483(0.322–0.726)	<0.001
<b>Overall</b>	<b>847</b>	<b>382(45.1%)</b>	<b>465(54.9%)</b>		<b>0.532(0.404–0.701)</b>	<b>&lt;0.001</b>
				 0.2 1 1.5 Hazard Ratio(HR)		